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Abstract 57 
 58 
Context: 2017 WHO Classification of Pituitary Tumors grades silent corticotroph adenomas (SCAs) 59 
as “high-risk adenomas” due to their aggressive clinical behavior (high probability of recurrence). 60 
However, studies comparing recurrence rates of SCAs with other non-functioning pituitary adenoma 61 
(NFPAs) subtypes have provided conflicting results. 62 
Objective: Estimate recurrence rates of SCAs after primary treatment (surgery±radiotherapy) and 63 
recurrence rate ratios (RRR) between SCAs and other NFPA subtypes.  64 
Methods: Systematic review of published literature reporting on outcomes of SCAs up to October 31, 65 
2017 was conducted. Recurrence rates, RRRs, 95% confidence intervals (CIs) were estimated from 66 
each study and pooled using random effects meta-analysis model. 67 
Results: For determination of SCAs recurrence rates, 14 studies (low risk of bias, 297 patients) were 68 
selected; recurrence rate was 5.96 (95% CI, 4.3-7.84) per 100 person-years. Based on studies with 69 
mean follow-up <5 or ≥5 years, 25% (cumulative incidence 0.25; 95% CI, 0.13-0.38) and 31% 70 
(cumulative incidence 0.31; 95% CI, 0.23-0.40) of SCAs had recurrence, respectively. Recurrence 71 
rates after surgery or surgery+radiotherapy were 5.41 (95% CI, 3.28-7.96) and 4.88 (95% CI, 0.67-72 
11.54) cases per 100 person-years, respectively. Analysis of 10 eligible studies (moderate risk of bias, 73 
244 SCAs, 1622 NFPAs) showed no significant RRR (1.44; 95% CI, 0.9-2.33, p=0.130) between the 74 
groups. Focus on tumors treated solely by surgery also revealed no significant RRR (1.17; 95% CI, 75 
0.79-1.75, p=0.429). 76 
Conclusions: Based on studies with mean follow-up ≥5 years, 31% of SCAs have recurrence. No 77 
evidence supporting higher recurrence risk of SCAs compared with other NFPA subtypes was found. 78 
 79 
 80 
 81 
 82 
 83 
 84 
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Introduction 85 
 86 
Silent corticotroph adenomas (SCAs) are pituitary neuroendocrine tumors (PitNETs) (1) 87 
demonstrating positive immunostaining for adrenocorticotropic hormone (ACTH) but not associated 88 
with clinical or biochemical evidence of cortisol excess. They arise from adenohypophyseal cells of 89 
Tpit lineage and account for 3-19% of non-functioning pituitary adenomas (NFPAs) (2-4). In contrast 90 
to Cushing’s disease which is mostly attributed to microadenomas, SCAs are diagnosed when they are 91 
large enough to cause pressure effects to surrounding structures necessitating surgical resection, 92 
ultimately leading to their pathological diagnosis (5,6).   93 
Traditionally, SCAs have been considered as aggressive lesions and, based on the 2017 WHO 94 
Classification of Pituitary Tumors, they are recognized as “high-risk pituitary adenomas” (3); this 95 
concept has mostly relied on studies reporting higher recurrence rates compared with other subtypes 96 
of NFPA (7-11), potentially leading for low threshold decisions on offering early adjuvant 97 
radiotherapy (RT). On the other hand, a number of series have not confirmed this (12-19) supporting 98 
the view that imaging follow-up and radiotherapy protocols at initial presentation should not differ 99 
from those adopted for other NFPA subtypes. These points, combined with the small number of cases 100 
included in each study (even in those from large pituitary centers) due to the rarity of this adenoma 101 
subtype and the differences in the follow-up duration between SCAs and other NFPAs within the 102 
same study (8,10), suggest that robust evidence on the long-term clinical behavior of SCAs after 103 
primary treatment is still lacking.   104 
In order to elucidate these controversial data and address reliably this topic, we conducted a 105 
systematic review and meta-analysis of published literature reporting on outcomes of SCAs; our first 106 
aim was to estimate the recurrence rates of SCAs after surgery followed or not by adjuvant RT, and 107 
our second objective was to clarify if SCAs carry a higher risk of recurrence after primary treatment 108 
compared to other subtypes of NFPAs. 109 
 110 
 111 
 112 
4 
 
Methods 113 
 114 
This systematic review and meta-analysis was conducted based on an a priori protocol, registered on 115 
PROSPERO (international database of prospectively registered systematic reviews, registration 116 
number CRD42017053862). The methods and results of the review are reported according to the 117 
Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement (20).  118 
 119 
Search strategy and eligibility criteria 120 
A systematic search of Medline, Embase and Cochrane Library Central databases was conducted to 121 
identify relevant articles published up to October 31, 2017. A detailed search strategy was developed 122 
by the study investigators with input from an information specialist (Supplementary Figure 1) (21). 123 
The reference lists of all retrieved articles were also included in the literature research/citation 124 
tracking. Only articles published in English were included, whilst duplicate studies and those with 125 
overlapping populations were excluded. Two independent reviewers (A.F. and A.L.) screened the 126 
initial search results for titles and abstracts pertaining to the research questions and then performed a 127 
full-text assessment of the potentially eligible published studies. Discrepancies in reviewers’ 128 
selections were resolved through discussion and consensus with a third reviewer (N.K.). Eligible 129 
studies were randomized controlled, non-randomized controlled, prospective and retrospective cohort, 130 
case-control and case series (with ≥5 cases) reporting on recurrence/regrowth rates of SCAs. Review 131 
articles, letters, commentaries and meeting abstracts were excluded. For the first review question, 132 
eligible studies were those including human subjects with SCA managed primarily by surgery 133 
followed or not by adjuvant RT. For the second review question, eligible studies were those 134 
comparing outcomes of human subjects with SCA (“exposed” cohort) with other subtypes of NFPA 135 
(“unexposed” cohort) managed primarily by surgery followed or not by adjuvant RT. Any article was 136 
excluded: i) if it was not reporting on recurrence/regrowth rates, ii) if imaging follow-up was 137 
unknown or less than 6 months. Recurrence/regrowth was defined as radiological progress of the 138 
tumor (increase in size of residual tumor or regrowth of adenoma when previously no residual tumor 139 
mass was present).  140 
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 141 
Data extraction 142 
Data from the selected studies were extracted independently by two investigators (A.F. and A.L.) and 143 
are presented in a standardized table. The information extracted from each article included: first 144 
author and year of publication, comparison group (patients with other subtypes of NFPA), number of 145 
patients in each cohort, age at diagnosis of the adenoma, follow-up duration and recurrence rates (in 146 
crude numbers and as a proportion). Data are also presented separately for two subgroups of patients: 147 
those treated and those not treated with adjuvant RT.  148 
 149 
Risk of bias assessment  150 
The Newcastle-Ottawa Scale (NOS) was used for evaluation of risk of bias of all included 151 
observational studies (22). Reviewers assessed independently the selection of studies, as well as the 152 
comparability and their outcomes using a rated system: low, moderate and high risk depending on the 153 
scoring for each section as presented in NOS assessment. Comparability of studies on the basis of 154 
adjuvant RT, extent of tumor removal and length of follow-up was main area of focus. Any scoring 155 
discrepancies were resolved through combined reassessment and consensus by all authors.  156 
 157 
Statistical analysis 158 
We conducted a meta-analysis using the random-effects model described by DerSimonian and Laird 159 
(23) to pool incidence rates (IRs) and recurrence rate ratios (RRRs) and their 95% confidence 160 
intervals (CIs). The random-effects model was chosen in order to account for heterogeneity across the 161 
included studies. For pooling recurrence rates, we performed Freeman-Turkey double arcsine 162 
transformation to address variance instability (24,25). When pooling RRRs, fixed continuity 163 
correction of 0.1 was used in case a study had no outcome in one of the arms (26). Statistical 164 
heterogeneity was tested by Q statistic generated from the x2 test, in which p values less than 0.10 165 
were considered significant. Heterogeneity was further quantified through the I-squared (I2) measure 166 
with values between 0% and 30% indicating no important heterogeneity, 30% and 60% moderate, 167 
60% and 75% substantial, and 75% to 100% considerable heterogeneity (27). I2 and p values of 168 
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statistical heterogeneity were given for all analyses. All statistical analyses were performed on Stata 169 
v14.0 software (StataCorp. LP, College Station (TX); 2015).  170 
For both outcomes (recurrence rates of SCAs and risk of recurrence of SCAs compared with other 171 
subtypes of NFPAs) of the meta-analysis, we estimated pooled IRs and RRRs with their 95% CIs. 172 
Due to significant variations in the length of follow-up between the included studies, we also 173 
conducted analysis accounting for duration of follow-up and we reported recurrence rates per 100 174 
person-years. In addition, we performed a subgroup analysis estimating recurrence rates separately for 175 
patients with follow-up less or more than 5 years.   176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
 184 
 185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
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Results 197 
 198 
Study identification and description 199 
The systematic search identified 1942 potentially eligible articles. After screening and assessment of 200 
eligibility, 14 articles were eligible for the first (8-10,12,13,15-18,28-32) and 10 for the second review 201 
question (8-10,12,13,15-18,29). All included studies were observational. The complete study selection 202 
process is described in Figure 1. 203 
For the calculation of the recurrence rates of SCAs, 297 patients were included with mean follow-up 204 
ranging between 2 and 7.4 years. For the assessment of the risk of recurrence of SCAs compared with 205 
other subtypes of NFPAs, 244 patients with SCAs followed-up for mean periods between 2 and 7.4 206 
years were compared to 1622 patients with other NFPA subtypes with mean follow-up duration 207 
ranging between 2 and 6.3 years. A summary of the included studies is given in Table 1. 208 
Data on recurrence of patients with SCA treated by surgery were extracted from 10 studies 209 
(8,12,13,15,17,18,28,30-32) (Supplementary Table 1) (21) and of those offered adjuvant RT from 4 210 
studies reporting on this management approach (13,15,28,32) (Supplementary Table 2) (21). For this 211 
subgroup analysis, 4 studies of Table 1 had to be excluded: 3 because the impact of adjuvant RT was 212 
not assessed separately (9,10,16) and one because administration of adjuvant RT was unknown (29). 213 
 214 
Risk of bias 215 
Studies contributing with data for the first question of the meta-analysis were at low (except one at 216 
moderate) risk of bias (Supplementary Table 3) (21) and those contributing with data for the second 217 
question of the meta-analysis were at moderate risk of bias (Supplementary Table 4) (21). 218 
 219 
Recurrence rates of SCAs 220 
Overall, the recurrence rate of SCAs was 5.96 (95% CI, 4.30-7.84) cases per 100 person-years 221 
(I2=33.57%, p=0.11) (Figure 2a). Recurrence rates were 4.88 (95% CI, 0.67-11.54) cases per 100 222 
person-years after adjuvant RT (I2=33.01%, p=0.21) and 5.41 (95% CI, 3.28-7.96) cases per 100 223 
person-years without adjuvant RT offered (I2=36.31%, p=0.12) (Figure 2b). 224 
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Given the variable follow-up duration of the patients with SCA in the included articles, recurrence 225 
incidences were estimated in two groups: those with mean follow-up <5 years or ≥5 years. In the 226 
studies that contributed with follow-up <5 years (8 studies), 25% of the patients had recurrence 227 
(cumulative incidence 0.25; 95% CI, 0.13-0.38) (I2=60.54%, p=0.01), whilst in those with follow-up 228 
≥5 years (6 studies), 31% had recurrence (cumulative incidence 0.31; 95% CI, 0.23-0.400) (I2=0.00%, 229 
p=0.48) (Figure 3a).  230 
After stratifying the studies for both adjuvant RT and length of follow-up, recurrence was detected in 231 
22% (cumulative incidence 0.22; 95% CI, 0.03-0.50) of the patients treated only by surgery and 232 
followed-up for <5 years (5 studies) (I2=76.91%, p=0.00) and in 31% (cumulative incidence 0.31; 233 
95% CI, 0.21-0.42) of those treated only by surgery and followed-up for ≥5 years (5 studies) 234 
(I2=0.36%, p=0.40) (Figure 3b). There was only one study with data on SCAs treated with adjuvant 235 
RT and followed-up for <5 years (28), reporting recurrence in 4 out of 6 patients. Furthermore, 3 236 
studies had data on the outcomes of irradiated patients followed-up for ≥5 years (13,15,32) but the 237 
number of cases was too small (n=14) to allow meta-analysis; amongst these 14 patients, 3 had SCAs 238 
recurrence. 239 
 240 
Risk of recurrence of SCAs compared with other subtypes of NFPAs  241 
In our meta-analysis, there was no significant difference in the recurrence rates between SCAs and 242 
other subtypes of NFPAs (RRR 1.44; 95% CI, 0.90-2.33, p=0.13) (I2=64.1%, p=0.003) (Figure 4a). 243 
This was also shown when tumors not offered adjuvant RT were compared (RRR 1.17; 95% CI, 0.79-244 
1.75, p=0.43) (I2=9.3%, p=0.357) (Figure 4b). Only one article included SCAs and other subtypes of 245 
NFPAs that had received adjuvant RT (15). In this study, recurrences were detected in 2 out of 6 246 
SCAs and in 4 out of 20 other NFPAs (mean follow-up 5.2 and 4.2 years, respectively). 247 
 248 
 249 
 250 
 251 
 252 
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Discussion 253 
 254 
In this systematic review and meta-analysis we assessed the recurrence rates of SCAs and their risk of 255 
recurrence compared to other subtypes of NFPAs. We found that overall, the recurrence rate of SCAs 256 
was 5.96 cases per 100 person-years and, based on studies with mean follow-up ≥5 years, 31% of the 257 
patients had recurrence. Furthermore, after accounting for length of follow-up, our meta-analysis 258 
showed that the rate ratio for recurrence between SCAs and other subtypes of NFPAs was not 259 
significantly evident. This was also confirmed when the comparison focused on tumors not offered 260 
adjuvant RT following primary surgery.   261 
Amongst NFPAs, the group of SCAs has attracted considerable attention due to the traditional 262 
concept that they demonstrate a more aggressive clinical behavior and to the fact that they can evolve 263 
into Cushing’s disease after long intervals of inactivity. The mechanisms of SCA genesis and growth 264 
are poorly understood and studies assessing their post-operative outcomes are limited with wide 265 
variations in the reported recurrence rates (5,33). This may be attributed to differences in the duration 266 
of follow-up, small sample size, review of irradiated and non-irradiated cases together and inclusion 267 
of patients already diagnosed with recurrence in the analyses. In order to overcome these limitations, 268 
we used strict inclusion and exclusion criteria focusing on cases after primary surgical treatment 269 
(combined or not with adjuvant RT) and taking into account the length of follow-up. We also 270 
excluded two patients from the Lopez et al. series (30) due to uncertainty on the diagnosis of SCA 271 
(both had temporary post-operative adrenal insufficiency and one of them had also Cushing’s 272 
phenotype), as well as two patients from the Alahmadi et al. study (12) due to presence of double 273 
adenomas (with ACTH and growth hormone staining).  274 
We found that recurrence rates were 4.88 (95% CI, 0.67-11.54) and 5.41 (95% CI, 4.10-7.49) cases 275 
per 100 person-years with or without adjuvant RT, respectively, with moderate heterogeneity between 276 
studies. It is generally accepted that RT is beneficial for long-term NFPA control after surgery 277 
(34,35); however, this treatment modality does not prevent tumor regrowth in all patients (36). 278 
Notably, the outcomes of SCAs after adjuvant RT were reported in only four studies (13,15,28,32) 279 
and direct comparison between the irradiated and non-irradiated groups leading to robust conclusions 280 
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were not possible. Thus, Bradley et al. (13), in a series of 28 patients (one of whom died during the 281 
post-operative period and was excluded from our analysis), had recurrence rates of 36% in the non-282 
irradiated and 20% in the irradiated ones (mean follow-up 7.4 years); Webb et al. (32), in a study of 283 
22 patients, found recurrence rate of 26% in the non-irradiated and 0% in the irradiated ones (mean 284 
follow-up 6.1 years). On the other hand, Baldeweg et al. (28), in a series of 15 cases, reported 11% 285 
and 67% recurrence rates in the non-irradiated and irradiated patients, respectively (mean follow-up 286 
4.8 years) and, Cho et al. (15), in a study of 28 SCAs, found tumor progression in 23% and 33% of 287 
the non-irradiated and irradiated patients, respectively (mean follow-up 5.2 years).  288 
It has been previously shown that most of the recurrences in NFPAs are detected in the first 5 post-289 
operative years (37,38). After stratifying the studies for modality of primary treatment and duration of 290 
follow-up, we found that in the group treated solely by surgery, recurrence was diagnosed in 22% of 291 
the patients monitored for <5 years (considerable heterogeneity between studies) and in 31% of those 292 
followed-up for ≥5 years (no heterogeneity amongst studies). The limited sample size of patients 293 
treated by surgery and adjuvant RT did not allow solid determination of the recurrence rates stratified 294 
for follow-up duration in this group; further studies are required to elucidate this issue. 295 
Interestingly, our meta-analysis did not confirm that SCAs have higher recurrence rates than the other 296 
NFPA subtypes (RRR 1.44; 95% CI, 0.9-2.33). Focus on reports with patients offered only surgery 297 
supported the same view (RRR 1.17; 95% CI, 0.79-1.75) with no important heterogeneity amongst the 298 
studies. In the only available article including patients with both types of adenomas that had been 299 
offered adjuvant RT, recurrence rates were 33% for SCAs and 20% for other NFPAs during mean 300 
observation periods 5.2 and 4.2 years, respectively (15). In this study, conventional fractionated RT 301 
was used in 67% of SCAs and 50% of NFPAs, whilst gamma knife radiosurgery was offered to 33% 302 
and 50% of SCAs and NFPAs, respectively; the radiation therapy protocol and the latency time 303 
between surgical treatment and adjuvant therapy did not differ between the two groups (15). Langlois 304 
et al., found higher adenoma progression rates in a series of 39 SCAs compared with 70 silent 305 
gonadotroph adenomas (36% vs. 10%, p=0.001) (10). It should be noted, however, that in the latter 306 
group, follow-up duration was significantly shorter (mean 6.7 vs 2.7 years). Similar results were also 307 
reported in the cohort of Jahangiri et al. (9) with 27% of SCAs recurring compared to 7% of NFPAs 308 
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(p<0.001); nonetheless, mean follow-up duration was short (2.4 and 3.1 years, respectively). On the 309 
other hand, in studies with similar follow-up length between the two groups (12,15,16), no difference 310 
in the recurrence rates was detected.  311 
Although our meta-analysis did not find evidence supporting an important increase in risk of 312 
recurrence of SCAs compared with other NFPA subtypes, an area potentially raising concerns on the 313 
prognosis of these tumors is the reported [in a few (13,15,32) but not in other (9,16) series] aggressive 314 
course of a subset of recurrent SCAs which continue to show multiple growths requiring various 315 
treatment modalities. Nonetheless, the number of these cases is extremely small and identification of 316 
predictive factors in a reliable way is currently not possible. It is of note that in a study by 317 
Ioachimescu et al. (16) comparing SCAs with other NFPA subtypes, there was no significant 318 
difference in the percentage of patients requiring multiple surgeries and RT. Furthermore, malignant 319 
transformation of SCAs has been described and this may also be seen in cases with gain in hormone 320 
secretion and development of overt Cushing’s syndrome (2,5,39,40). In a recent review of all 321 
published cases of malignant NFPAs, staining for ACTH was reported in 9 out of 38 patients (23.7%) 322 
(41); again, the very small number of total cases make the interpretation of this rate difficult. 323 
Therefore, it would be reasonable to consider that decisions on the management strategies for the total 324 
group of SCAs should not rely on the outcomes of these rare subgroups of aggressive SCAs.   325 
Potential sources of heterogeneity in our meta-analysis include the variable sample size and follow-up 326 
duration of patients between different studies and between groups under comparison within the same 327 
study, as well as variations in the radiotherapy techniques/protocols and in the extent of tumor 328 
removal/location of residual tumor after primary surgery [which has been reported as a factor 329 
predicting recurrence risk in NFPAs (17,42,43)].  330 
The strengths of our study include the comprehensive literature search, the strict protocol-driven 331 
selection of studies, the duplicate process for study selection and evaluation and the performance of 332 
analyses also taking into account the length of follow-up. Limitations include the retrospective, 333 
observational nature of the available reports, the moderate to substantial heterogeneity in the meta-334 
analysis of a number of outcomes, the absence of data on pathological/molecular markers of 335 
aggressiveness and the small number of cases offered adjuvant RT not allowing sound estimation of 336 
12 
 
outcomes in this subgroup. Finally, given that transcription factor expression analysis was not 337 
available, the possibility of inclusion of corticotroph adenohypophyseal cell differentiation tumors in 338 
the group of “null cell” NFPAs cannot be excluded. Nonetheless, based on a recent report (44), it is 339 
anticipated that only a small proportion of hormone immunonegative adenomas express corticotroph 340 
lineage specific transcription factors; future studies will elucidate this field.  341 
In conclusion, our systematic review and meta-analysis of studies of moderate risk of bias has not 342 
confirmed higher risk of SCAs recurrence compared with other NFPA subtypes. Our data point out 343 
the need for further methodologically robust (adequately powered, with appropriate adjustment for all 344 
possible confounding factors and of prolonged follow-up) studies comparing SCAs with other NFPA 345 
subtypes and clarifying their true biological behavior, as well as whether they should be indeed (as per 346 
2017 WHO recommendation) classified as high-risk pituitary adenomas. Furthermore, studies 347 
particularly looking at the rare subgroups of SCAs with multiple growths and resistance to various 348 
treatments, malignant transformation or development of overt Cushing’s aiming to shed light on their 349 
pathophysiology and factors predicting their prognosis will be of major significance in the field and 350 
will facilitate the development of valuable evidence-based management protocols in the area of 351 
PitNETs.  352 
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Legends for figures and tables 502 
 503 
Table 1: Characteristics of the included studies for both review questions 504 
 505 
Figure 1: Flowchart showing the study selection process. 506 
 507 
Figure 2: (a) Recurrence rates of silent corticotroph adenomas per 100 person-years. (b) Recurrence 508 
rates of silent corticotroph adenomas managed without or with adjuvant radiotherapy after 509 
primary surgery (IR: incidence rate; CI:confidence intervals). 510 
 511 
Figure 3: (a) Recurrence rates of silent corticotroph adenomas according to mean follow-up (≥5 or <5 512 
years). (b) Recurrence rates of silent corticotroph adenomas treated primarily only by 513 
surgery according to mean follow-up (≥5 or <5 years) (CI:confidence intervals). 514 
 515 
Figure 4: (a) Recurrence rate ratios between silent corticotroph adenomas and other subtypes of non-516 
functioning pituitary adenomas. (b) Recurrence rate ratios between silent corticotroph 517 
adenomas and other subtypes of non-functioning pituitary adenomas treated primarily only 518 
by surgery (RRR: recurrence rate ratio; SCA: silent corticotroph adenoma, NFPA: non-519 
functioning pituitary adenoma; CI:confidence intervals). 520 
 521 
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